Silencing the BRRIAR promoter not only reduces its expression but also diminishes enhancer cluster activity, leading to downregulation of BHLHE40. This suggests that BRRIAR transcription is required for the full enhancer activity in a subset of ER + breast tumors. The gene discussed is ESR1; the disease is breast neoplasm.